Bioinformatics: Biology’s Final Frontier
It is hard to imagine an investment more important than healthcare. As a human being, we should not concern ourselves with profit motives when we have the means to make such an impact for the greater good. Health is something that profoundly affects the quality and length of our lives.
With this consideration in mind, many investors will want to be confident in their choices (will the drug be a success?) and also desire a positive ROI (will it make money?). Contributions to the success of any project may come from disparate intentions.
Far-sighted investors who choose something as significant as longevity research stand in the position to benefit the lives of the present and future generations while accruing financial benefits that better enable them to make a positive impact on the world.
The first question that should be addressed is if a new drug actually has a chance at either slowing the aging process (or reversing it), and consequently improving the quality of life and health for the world’s population.
Modern medicine has realized the rate at which we age can be augmented. Aging is linked to a series of biological processes such as telomere shortening and mitochondrial dysfunction.
Regenerative medicine may not ever make the human body immortal like some species of jellyfish, but it has massive potential to cure a slew of degenerative diseases and imbue us with lives devoid of the physical suffering that comes with age.
Bioinformatics is the foundation of all efforts to extend healthspan. As another promising avenue in our continuous quest for longer and healthier lives has produced fantastic results, even at this early stage of its development. Bioinformatics uses computational technology to better understand biology, like the interactions between an organism and its environment
The breakthroughs to medical science of this industry offers profound hope for the future of medical treatment. Researchers have used artificial intelligence (AI) to predict fatal heart attacks up to five years in advance. AI is capable of analyzing biomarkers like the fat radiomic profile (FRP) to determine if blood vessels are inflamed, scarred, or changed — all signs of an impending heart attack.
Considering that patients presenting chest pain are sent home 75% of the time, as no abnormalities appear on the standard coronary CT angiogram (CCTA) yet some subsequently suffer heart attacks, it is truly stellar that the technology now exist that can significantly obviate the risk of death, and save the lives of so many who would otherwise succumb to the world’s number one cause of death.
Bioinformatics isn’t just transforming cardiology.
Machine learning approaches to oncology have been used to identify tumor-specific antigens, the significance being an eventual increase in feasibility and accuracy of personalized cancer treatment. This avenue of research may result in personalized vaccines as more neoantigens are discovered.
Bioinformatics continues to propel forward as personalized medical treatment, drug discovery, and research in molecular biology are compelling private organizations and governments to fund this vital research. Last year, the market stood at 12.37 billion dollars and is expected to grow to 23.42 billion by 2026.
Cutting-edge companies like BioViva Science are propelling longevity research forward deserves our utmost interest and any allocation of capital towards such auspicious industries is well worth it, as they stand as pillars for healthier, longer lives for present and future generations.
Works Cited and Suggested Reading
Aurisicchio, Luigi, et al. “The perfect personalized cancer therapy: cancer vaccines against neoantigens.” Journal of Experimental & Clinical Cancer Research 37.1 (2018): 1–10.
Oikonomou, Evangelos K., et al. “A novel machine learning-derived radiotranscriptomic signature of perivascular fat improves cardiac risk prediction using coronary CT angiography.” European heart journal 40.43 (2019): 3529–3543.
Authored by John Ryan
John Ryan is an independent writer and an avid enthusiast of blockchain technology. He received his University education at Northern Michigan University, as a history major, where he was inducted into the Phi Beta Kappa Society for academic excellence. While in Michigan, he also trained as an athlete at the United States Olympic Education Center, where he achieved the status of a multiple-time University All-American in Greco-Roman wrestling. He has authored several plays and a collection of poetry. Some of his major areas of interests includes: Finance, Literature, and Religious Studies.
John is available to contact via email at: arete.aphthiton@gmail.com
